These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2523 related items for PubMed ID: 29911393

  • 1. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE, Ahuja T, Bridgeman MB.
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A, Badimon JJ, Santos-Gallego CG.
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B, Wang Y, Zhang Y, Yan B.
    Curr Top Med Chem; 2019 Dec; 19(20):1818-1849. PubMed ID: 31456521
    [Abstract] [Full Text] [Related]

  • 4. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI.
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [Abstract] [Full Text] [Related]

  • 5. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ.
    Circulation; 2016 Sep 06; 134(10):752-72. PubMed ID: 27470878
    [Abstract] [Full Text] [Related]

  • 6. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y.
    Adv Ther; 2019 Oct 06; 36(10):2567-2586. PubMed ID: 31444707
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A.
    Int J Cardiol; 2016 Jun 01; 212():29-36. PubMed ID: 27017118
    [Abstract] [Full Text] [Related]

  • 8. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG.
    Drugs Today (Barc); 2017 Mar 01; 53(3):191-202. PubMed ID: 28447076
    [Abstract] [Full Text] [Related]

  • 9. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D, Javor E, Lucijanić T, Skelin M.
    Ann Med; 2017 Feb 01; 49(1):51-62. PubMed ID: 27535028
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I.
    Postgrad Med; 2019 Jan 01; 131(1):31-42. PubMed ID: 30449220
    [Abstract] [Full Text] [Related]

  • 11. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW.
    Vasc Health Risk Manag; 2016 Jan 01; 12():393-405. PubMed ID: 27822054
    [Abstract] [Full Text] [Related]

  • 12. [Outcome studies on SGLT-2 inhibitors].
    Seufert J, Laubner K.
    Internist (Berl); 2019 Sep 01; 60(9):903-911. PubMed ID: 31375850
    [Abstract] [Full Text] [Related]

  • 13. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Lupsa BC, Inzucchi SE.
    Diabetologia; 2018 Oct 01; 61(10):2118-2125. PubMed ID: 30132031
    [Abstract] [Full Text] [Related]

  • 14. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY, Petrie MC, McMurray JJV, Sattar N.
    Arterioscler Thromb Vasc Biol; 2020 Mar 01; 40(3):506-522. PubMed ID: 31996025
    [Abstract] [Full Text] [Related]

  • 15. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A, Mittal S, Monika, Dhingra R, Dhingra N.
    Curr Diabetes Rev; 2020 Mar 01; 16(7):716-732. PubMed ID: 31951170
    [Abstract] [Full Text] [Related]

  • 16. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A.
    J Diabetes Complications; 2018 Jul 01; 32(7):720-725. PubMed ID: 29880432
    [Abstract] [Full Text] [Related]

  • 17. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA, Hallow KM.
    J Clin Pharmacol; 2018 Mar 01; 58(3):377-385. PubMed ID: 29144539
    [Abstract] [Full Text] [Related]

  • 18. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S.
    Crit Pathw Cardiol; 2017 Sep 01; 16(3):93-95. PubMed ID: 28742644
    [Abstract] [Full Text] [Related]

  • 19. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
    Kuchay MS, Farooqui KJ, Mishra SK, Mithal A.
    Adv Exp Med Biol; 2021 Sep 01; 1307():213-230. PubMed ID: 32006266
    [Abstract] [Full Text] [Related]

  • 20. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
    d'Emden M, Amerena J, Deed G, Pollock C, Cooper ME.
    Diabetes Res Clin Pract; 2018 Feb 01; 136():23-31. PubMed ID: 29196150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 127.